nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

12.01.2022 | Review Article

EMT and Inflammation: Crossroads in HCC

verfasst von: Burcu Sengez, Brian I. Carr, Hani Alotaibi

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma is one of the major causes of cancer-related deaths worldwide and is associated with several inflammatory mediators, since 90% of HCCs occur based on chronic hepatitis B or C, alcoholism or increasingly metabolic syndrome-associated inflammation. EMT is a physiological process, with coordinated changes in epithelial gene signatures and is regulated by multiple factors, including cytokines and growth factors such as TGFβ, EGF, and FGF. Recent reports propose a strong association between EMT and inflammation, which is also correlated with tumor aggressiveness and poor outcomes. Cellular heterogeneity results collectively as an outcome of EMT, inflammation, and the tumor microenvironment, and it plays a fundamental role in the progression, complexity of cancer, and chemoresistance. In this review, we highlight recent developments concerning the association of EMT and inflammation in the context of HCC progression. Identifying potential EMT-related biomarkers and understanding EMT regulatory molecules will likely contribute to promising developments in clinical practice and will be a valuable tool for predicting metastasis in general and specifically in HCC.

Brabletz T. To differentiate or not–routes towards metastasis. Nat Rev Cancer. 2012;12(6):425–36. https://doi.org/10.1038/nrc3265.CrossRefPubMed

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8. https://doi.org/10.1172/JCI39104.CrossRefPubMedPubMedCentral

Kim DH, Xing T, Yang Z, Dudek R, Lu Q, et al. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview. J Clin Med. 2017;7(1). https://doi.org/10.3390/jcm7010001.

Theveneau E, Mayor R. Neural crest delamination and migration: from epithelium-to-mesenchyme transition to collective cell migration. Dev Biol. 2012;366(1):34–54. https://doi.org/10.1016/j.ydbio.2011.12.041.CrossRefPubMed

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

Yokoyama S, Asahara H. The myogenic transcriptional network. Cell Mol Life Sci. 2011;68(11):1843–9. https://doi.org/10.1007/s00018-011-0629-2.CrossRefPubMedPubMedCentral

Haensel D, Dai X. Epithelial-to-mesenchymal transition in cutaneous wound healing: where we are and where we are heading. Dev Dyn. 2018;247(3):473–80. https://doi.org/10.1002/dvdy.24561.CrossRefPubMed

Stone RC, Pastar I, Ojeh N, Chen V, Liu S, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):495–506. https://doi.org/10.1007/s00441-016-2464-0.CrossRefPubMedPubMedCentral

Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020;30(10):764–76. https://doi.org/10.1016/j.tcb.2020.07.003.CrossRefPubMedPubMedCentral

10.

Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell. 2019;49(3):361–74. https://doi.org/10.1016/j.devcel.2019.04.010.CrossRefPubMedPubMedCentral

11.

Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13(6): 100773. https://doi.org/10.1016/j.tranon.2020.100773.CrossRefPubMedPubMedCentral

12.

Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol. 2017;11(7):805–23. https://doi.org/10.1002/1878-0261.12095.CrossRefPubMedPubMedCentral

13.

Zhou C, Liu J, Tang Y, Liang X. Inflammation linking EMT and cancer stem cells. Oral Oncol. 2012;48(11):1068–75. https://doi.org/10.1016/j.oraloncology.2012.06.005.CrossRefPubMed

14.

Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2021. https://doi.org/10.1016/j.semcancer.2021.02.015.CrossRefPubMed

15.

van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5(8):1169–79. https://doi.org/10.2217/fon.09.91.CrossRefPubMed

16.

Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401–35. https://doi.org/10.1007/978-3-0348-0837-8_16.CrossRefPubMed

17.

Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory mechanisms of HCC development. Cancers (Basel). 2020;12(3). https://doi.org/10.3390/cancers12030641.

18.

Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6. https://doi.org/10.1038/s41698-018-0048-z.CrossRefPubMedPubMedCentral

19.

Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013;22(3):305–10.PubMed

20.

Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin. 2010;31(11):1409–20. https://doi.org/10.1038/aps.2010.142.CrossRefPubMedPubMedCentral

21.

Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80(6):1197–213. https://doi.org/10.1189/jlb.0506297.CrossRefPubMed

22.

Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23). https://doi.org/10.3390/ijms20236008.

23.

Ding K, Fan L, Chen S, Wang Y, Yu H, et al. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep. 2015;34(6):3297–303. https://doi.org/10.3892/or.2015.4306.CrossRefPubMed

24.

Dong Q, Zhu X, Dai C, Zhang X, Gao X, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016;7(11):12997–3012. https://doi.org/10.18632/oncotarget.7016.CrossRefPubMedPubMedCentral

25.

Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65. https://doi.org/10.1016/j.cyto.2017.07.004.CrossRefPubMed

26.

Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483–90. https://doi.org/10.1002/hep.24703.CrossRefPubMed

27.

Kim H, Park YN. Hepatocellular carcinomas expressing ‘stemness’-related markers: clinicopathological characteristics. Dig Dis. 2014;32(6):778–85. https://doi.org/10.1159/000368021.CrossRefPubMed

28.

Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, et al. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep. 2014;31(6):2660–8. https://doi.org/10.3892/or.2014.3129.CrossRefPubMed

29.

Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511.CrossRefPubMed

30.

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96. https://doi.org/10.1038/nrm3758.CrossRefPubMedPubMedCentral

31.

Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808. https://doi.org/10.1016/j.jhep.2016.05.007.CrossRefPubMed

32.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.CrossRefPubMedPubMedCentral

33.

Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, et al. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 2012;19(5):1700–6. https://doi.org/10.1245/s10434-011-1772-6.CrossRefPubMed

34.

Sreekumar R, Emaduddin M, Al-Saihati H, Moutasim K, Chan J, et al. Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell Death Dis. 2019;10(10):703. https://doi.org/10.1038/s41419-019-1885-6.CrossRefPubMedPubMedCentral

35.

Al-Ismaeel Q, Neal CP, Al-Mahmoodi H, Almutairi Z, Al-Shamarti I, et al. ZEB1 and IL-6/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 proteins. Br J Cancer. 2019;121(1):65–75. https://doi.org/10.1038/s41416-019-0483-9.CrossRefPubMedPubMedCentral

36.

de Barrios O, Sanchez-Moral L, Cortes M, Ninfali C, Profitos-Peleja N, et al. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells. Gut. 2019;68(12):2129–41. https://doi.org/10.1136/gutjnl-2018-317294.CrossRefPubMed

37.

Katsura A, Tamura Y, Hokari S, Harada M, Morikawa M, et al. ZEB1-regulated inflammatory phenotype in breast cancer cells. Mol Oncol. 2017;11(9):1241–62. https://doi.org/10.1002/1878-0261.12098.CrossRefPubMedPubMedCentral

38.

Ricciardi M, Zanotto M, Malpeli G, Bassi G, Perbellini O, et al. Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. Br J Cancer. 2015;112(6):1067–75. https://doi.org/10.1038/bjc.2015.29.CrossRefPubMedPubMedCentral

39.

Gugnoni M, Ciarrocchi A. Long noncoding RNA and epithelial mesenchymal transition in cancer. Int J Mol Sci. 2019;20(8). https://doi.org/10.3390/ijms20081924.

40.

Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6–7):303–14. https://doi.org/10.1002/emmm.200900043.CrossRefPubMedPubMedCentral

41.

Aruga N, Kijima H, Masuda R, Onozawa H, Yoshizawa T, et al. Epithelial-mesenchymal transition (EMT) is correlated with patient’s prognosis of lung squamous cell carcinoma. Tokai J Exp Clin Med. 2018;43(1):5–13.PubMed

42.

Deshmukh AP, Vasaikar SV, Tomczak K, Tripathi S, den Hollander P, et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc Natl Acad Sci USA. 2021;118(19). https://doi.org/10.1073/pnas.2102050118.

43.

Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8. https://doi.org/10.1126/scisignal.2005189.

44.

Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512–20. https://doi.org/10.1111/j.1349-7006.2007.00550.x.CrossRefPubMed

45.

Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;22(5–6):455–61. https://doi.org/10.1016/j.semcancer.2012.05.004.CrossRefPubMed

46.

Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-beta - an excellent servant but a bad master. J Transl Med. 2012;10:183. https://doi.org/10.1186/1479-5876-10-183.CrossRefPubMedPubMedCentral

47.

Yang L, Moses HL. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res. 2008;68(22):9107–11. https://doi.org/10.1158/0008-5472.CAN-08-2556.CrossRefPubMedPubMedCentral

48.

Dituri F, Mancarella S, Cigliano A, Chieti A, Giannelli G. TGF-beta as multifaceted orchestrator in HCC progression: signaling, EMT, immune microenvironment, and novel therapeutic perspectives. Semin Liver Dis. 2019;39(1):53–69. https://doi.org/10.1055/s-0038-1676121.CrossRefPubMed

49.

Su Q, Fan M, Wang J, Ullah A, Ghauri MA, et al. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1alpha/TGF-beta feed-forward loop in hepatocellular carcinoma. Cell Death Dis. 2019;10(12):939. https://doi.org/10.1038/s41419-019-2173-1.CrossRefPubMedPubMedCentral

50.

Zhang J, Zhang Q, Lou Y, Fu Q, Chen Q, et al. Hypoxia-inducible factor-1alpha/interleukin-1beta signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment. Hepatology. 2018;67(5):1872–89. https://doi.org/10.1002/hep.29681.CrossRefPubMed

51.

Tam SY, Wu VWC, Law HKW. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1alpha and beyond. Front Oncol. 2020;10:486. https://doi.org/10.3389/fonc.2020.00486.CrossRefPubMedPubMedCentral

52.

Yeo CD, Kang N, Choi SY, Kim BN, Park CK, et al. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation. Korean J Intern Med. 2017;32(4):589–99. https://doi.org/10.3904/kjim.2016.302.CrossRefPubMedPubMedCentral

53.

Kung-Chun Chiu D, Pui-Wah Tse A, Law CT, Ming-Jing Xu I, Lee D, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death Dis. 2019;10(12):934. https://doi.org/10.1038/s41419-019-2155-3.

54.

Liu Z, Tu K, Wang Y, Yao B, Li Q, et al. Hypoxia accelerates aggressiveness of hepatocellular carcinoma cells involving oxidative stress, epithelial-mesenchymal transition and non-canonical hedgehog signaling. Cell Physiol Biochem. 2017;44(5):1856–68. https://doi.org/10.1159/000485821.CrossRefPubMed

55.

Lv C, Wang S, Lin L, Wang C, Zeng K, et al. USP14 maintains HIF1-alpha stabilization via its deubiquitination activity in hepatocellular carcinoma. Cell Death Dis. 2021;12(9):803. https://doi.org/10.1038/s41419-021-04089-6.CrossRefPubMedPubMedCentral

56.

Yan G, Wang X, Sun C, Zheng X, Wei H, et al. Chronic alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis via immune disturbances. Sci Rep. 2017;7(1):2567. https://doi.org/10.1038/s41598-017-02887-7.CrossRefPubMedPubMedCentral

57.

Mitra A, Yan J, Xia X, Zhou S, Chen J, et al. IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition(+) metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient beta2-spectrin(+/-) mice. Hepatology. 2017;65(4):1222–36. https://doi.org/10.1002/hep.28951.CrossRefPubMed

58.

Bergmann J, Muller M, Baumann N, Reichert M, Heneweer C, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology. 2017;65(1):89–103. https://doi.org/10.1002/hep.28874.CrossRefPubMed

59.

Chen Y, Meng L, Shang H, Dou Q, Lu Z, et al. Beta2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through beta-catenin. Cell Death Dis. 2018;9(4):424. https://doi.org/10.1038/s41419-018-0456-6.CrossRefPubMedPubMedCentral

60.

Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun. 2013;46:25–34. https://doi.org/10.1016/j.jaut.2013.07.008.CrossRefPubMed

61.

Li Y, Chen G, Han Z, Cheng H, Qiao L, et al. IL-6/STAT3 Signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells. Onco Targets Ther. 2020;13:9721–30. https://doi.org/10.2147/OTT.S262089.CrossRefPubMedPubMedCentral

62.

Wael H, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, et al. Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma. Lung Cancer. 2014;85(2):131–40. https://doi.org/10.1016/j.lungcan.2014.05.001.CrossRefPubMed

63.

Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678–89. https://doi.org/10.1038/nrm2009.CrossRefPubMed

64.

Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17(11):722–35. https://doi.org/10.1038/nrm.2016.94.CrossRefPubMed

65.

Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1(5):466–76. https://doi.org/10.4161/cbt.1.5.159.CrossRefPubMed

66.

Aster JC, Pear WS, Blacklow SC. The varied roles of notch in cancer. Annu Rev Pathol. 2017;12:245–75. https://doi.org/10.1146/annurev-pathol-052016-100127.CrossRefPubMed

67.

Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017;17(3):145–59. https://doi.org/10.1038/nrc.2016.145.CrossRefPubMed

68.

Zhu C, Ho YJ, Salomao MA, Dapito DH, Bartolome A, et al. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J Hepatol. 2021;74(3):613–26. https://doi.org/10.1016/j.jhep.2020.09.032.CrossRefPubMed

69.

Shen H, McElhinny AS, Cao Y, Gao P, Liu J, et al. The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 2006;20(6):675–88. https://doi.org/10.1101/gad.1383706.CrossRefPubMedPubMedCentral

70.

Wang J, Zhang SM, Wu JM, Lu ZC, Yang JR, et al. Mastermind-like transcriptional coactivator 1 overexpression predicts poor prognosis in human with hepatocellular carcinoma. Ann Clin Lab Sci. 2016;46(5):502–7.PubMed

71.

Zema S, Pelullo M, Nardozza F, Felli MP, Screpanti I, et al. A dynamic role of mastermind-like 1: a journey through the main (path)ways between development and cancer. Front Cell Dev Biol. 2020;8: 613557. https://doi.org/10.3389/fcell.2020.613557.CrossRefPubMedPubMedCentral

72.

Saha SK, Choi HY, Yang GM, Biswas PK, Kim K, et al. GPR50 promotes hepatocellular carcinoma progression via the notch signaling pathway through direct interaction with ADAM17. Mol Ther Oncolytics. 2020;17:332–49. https://doi.org/10.1016/j.omto.2020.04.002.CrossRefPubMedPubMedCentral

73.

Garg M. Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer. World J Stem Cells. 2013;5(4):188–95. https://doi.org/10.4252/wjsc.v5.i4.188.CrossRefPubMedPubMedCentral

74.

Wang Z, Li Y, Kong D, Sarkar FH. The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010;11(6):745–51. https://doi.org/10.2174/138945010791170860.CrossRefPubMedPubMedCentral

75.

Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 2004;23(5):1155–65. https://doi.org/10.1038/sj.emboj.7600069.CrossRefPubMedPubMedCentral

76.

Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18(1):99–115. https://doi.org/10.1101/gad.276304.CrossRefPubMedPubMedCentral

77.

Pires BR, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Diaz JA, et al. NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE. 2017;12(1): e0169622. https://doi.org/10.1371/journal.pone.0169622.CrossRefPubMedPubMedCentral

78.

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416–28. https://doi.org/10.1016/j.ccr.2009.03.016.CrossRefPubMedPubMedCentral

79.

Abbott DW, Laszczak M, Lewis JD, Su H, Moore SC, et al. Structural characterization of macroH2A containing chromatin. Biochemistry. 2004;43(5):1352–9. https://doi.org/10.1021/bi035859i.CrossRefPubMed

80.

Chang H, Li J, Qu K, Wan Y, Liu S, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFkappaB pathway in hepatocellular carcinoma. Cell Death Dis. 2020;11(5):332. https://doi.org/10.1038/s41419-020-2528-7.CrossRefPubMedPubMedCentral

81.

Jing Y, Han Z, Liu Y, Sun K, Zhang S, et al. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS ONE. 2012;7(8): e43272. https://doi.org/10.1371/journal.pone.0043272.CrossRefPubMedPubMedCentral

82.

Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014;1843(11):2563–82. https://doi.org/10.1016/j.bbamcr.2014.05.014.CrossRefPubMed

83.

Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–71. https://doi.org/10.1111/febs.14466.CrossRefPubMedPubMedCentral

84.

Huang F, Geng XP. Chemokines and hepatocellular carcinoma. World J Gastroenterol. 2010;16(15):1832–6. https://doi.org/10.3748/wjg.v16.i15.1832.CrossRefPubMedPubMedCentral

85.

Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013;4(12):2171–85. https://doi.org/10.18632/oncotarget.1426.CrossRefPubMedPubMedCentral

86.

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–72. https://doi.org/10.1038/nri.2017.49.CrossRefPubMedPubMedCentral

87.

Liang CM, Chen L, Hu H, Ma HY, Gao LL, et al. Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol. 2015;7(10):1390–402. https://doi.org/10.4254/wjh.v7.i10.1390.CrossRefPubMedPubMedCentral

88.

Liu Q, Li A, Tian Y, Wu JD, Liu Y, et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016;31:61–71. https://doi.org/10.1016/j.cytogfr.2016.08.002.CrossRefPubMedPubMedCentral

89.

Batlle R, Andres E, Gonzalez L, Llonch E, Igea A, et al. Regulation of tumor angiogenesis and mesenchymal-endothelial transition by p38alpha through TGF-beta and JNK signaling. Nat Commun. 2019;10(1):3071. https://doi.org/10.1038/s41467-019-10946-y.CrossRefPubMedPubMedCentral

90.

Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, et al. TGFbeta suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1749. https://doi.org/10.1038/s41467-020-15404-8.CrossRefPubMedPubMedCentral

91.

Yang L. TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev. 2010;29(2):263–71. https://doi.org/10.1007/s10555-010-9226-3.CrossRefPubMedPubMedCentral

92.

Barashi N, Weiss ID, Wald O, Wald H, Beider K, et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013;58(3):1021–30. https://doi.org/10.1002/hep.26403.CrossRefPubMed

93.

Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S, et al. Biological and clinical significance of the CCR5/CCL5 axis in hepatocellular carcinoma. Cancers (Basel). 2020;12(4). https://doi.org/10.3390/cancers12040883.

94.

Kopitar-Jerala N. The role of interferons in inflammation and inflammasome activation. Front Immunol. 2017;8:873. https://doi.org/10.3389/fimmu.2017.00873.CrossRefPubMedPubMedCentral

95.

Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11: 606489. https://doi.org/10.3389/fimmu.2020.606489.CrossRefPubMedPubMedCentral

96.

Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. JAKSTAT. 2013;2(1): e23820. https://doi.org/10.4161/jkst.23820.CrossRefPubMedPubMedCentral

97.

Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86. https://doi.org/10.1038/nri1604.CrossRefPubMed

98.

Wang H, Brown J, Garcia CA, Tang Y, Benakanakere MR, et al. The role of glycogen synthase kinase 3 in regulating IFN-beta-mediated IL-10 production. J Immunol. 2011;186(2):675–84. https://doi.org/10.4049/jimmunol.1001473.CrossRefPubMed

99.

Romerio F, Riva A, Zella D. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Br J Cancer. 2000;83(4):532–8. https://doi.org/10.1054/bjoc.2000.1263.CrossRefPubMedPubMedCentral

100.

Yeh YH, Hsiao HF, Yeh YC, Chen TW, Li TK. Inflammatory interferon activates HIF-1alpha-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway. J Exp Clin Cancer Res. 2018;37(1):70. https://doi.org/10.1186/s13046-018-0730-6.CrossRefPubMedPubMedCentral

101.

Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69(3):855–62. https://doi.org/10.1158/0008-5472.CAN-08-2831.CrossRefPubMed

102.

Zhang Z, Zhu Y, Xu D, Li TE, Li JH, et al. IFN-alpha facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma. Am J Transl Res. 2021;13(1):301–13.PubMedPubMedCentral

103.

Wang H, Liu J, Hu X, Liu S, He B. Prognostic and therapeutic values of tumor necrosis factor-alpha in hepatocellular carcinoma. Med Sci Monit. 2016;22:3694–704. https://doi.org/10.12659/msm.899773.CrossRefPubMedPubMedCentral

104.

Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2):311–20. https://doi.org/10.1172/JCI1368.CrossRefPubMedPubMedCentral

105.

Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, et al. Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects. Eur J Med Res. 2010;15(Suppl 2):120–2. https://doi.org/10.1186/2047-783x-15-s2-120.CrossRefPubMedPubMedCentral

106.

Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28(33):2940–7. https://doi.org/10.1038/onc.2009.180.CrossRefPubMedPubMedCentral

107.

Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT. 2014;3(1): e28975. https://doi.org/10.4161/jkst.28975.CrossRefPubMedPubMedCentral

108.

Gyamfi J, Lee YH, Eom M, Choi J. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep. 2018;8(1):8859. https://doi.org/10.1038/s41598-018-27184-9.CrossRefPubMedPubMedCentral

109.

Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124(2):184–7. https://doi.org/10.1182/blood-2014-03-562538.CrossRefPubMedPubMedCentral

110.

Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19(2):353–8. https://doi.org/10.1093/annonc/mdm448.CrossRefPubMed

111.

Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA, Jr. Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol. 1985;121(3):394–403.

112.

Faletti L, Peintner L, Neumann S, Sandler S, Grabinger T, et al. TNFalpha sensitizes hepatocytes to FasL-induced apoptosis by NFkappaB-mediated Fas upregulation. Cell Death Dis. 2018;9(9):909. https://doi.org/10.1038/s41419-018-0935-9.CrossRefPubMedPubMedCentral

113.

Wang Y, Xu J, Zhang X, Wang C, Huang Y, et al. TNF-alpha-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis. Cell Death Dis. 2017;8(3): e2715. https://doi.org/10.1038/cddis.2017.129.CrossRefPubMedPubMedCentral

114.

Wang H, Wang HS, Zhou BH, Li CL, Zhang F, et al. Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS ONE. 2013;8(2): e56664. https://doi.org/10.1371/journal.pone.0056664.CrossRefPubMedPubMedCentral

115.

Jang MK, Kim HS, Chung YH. Clinical aspects of tumor necrosis factor-alpha signaling in hepatocellular carcinoma. Curr Pharm Des. 2014;20(17):2799–808. https://doi.org/10.2174/13816128113199990587.CrossRefPubMed

116.

Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-alpha and complement component 3 on coagulation. Sci Rep. 2018;8(1):1812. https://doi.org/10.1038/s41598-018-20220-8.CrossRefPubMedPubMedCentral

117.

Neophytou, C.M., M. Panagi, T. Stylianopoulos, and P. Papageorgis, The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers (Basel), 2021. 13(9). https://doi.org/10.3390/cancers13092053.

118.

Kim J, Bae JS. Tumor-Associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. https://doi.org/10.1155/2016/6058147.CrossRefPubMedPubMedCentral

119.

Shirabe K, Mano Y, Muto J, Matono R, Motomura T, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today. 2012;42(1):1–7. https://doi.org/10.1007/s00595-011-0058-8.CrossRefPubMed

120.

Li Z, Wu T, Zheng B, Chen L. Individualized precision treatment: targeting TAM in HCC. Cancer Lett. 2019;458:86–91. https://doi.org/10.1016/j.canlet.2019.05.019.CrossRefPubMed

121.

Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013: 187204. https://doi.org/10.1155/2013/187204.CrossRefPubMed

122.

Faurobert E, Bouin AP, Albiges-Rizo C. Microenvironment, tumor cell plasticity, and cancer. Curr Opin Oncol. 2015;27(1):64–70. https://doi.org/10.1097/CCO.0000000000000154.CrossRefPubMed

123.

Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep. 2017;3(4):218–29. https://doi.org/10.1007/s40610-017-0073-7.CrossRefPubMedPubMedCentral

124.

Cao MX, Jiang YP, Tang YL, Liang XH. The crosstalk between lncRNA and microRNA in cancer metastasis: orchestrating the epithelial-mesenchymal plasticity. Oncotarget. 2017;8(7):12472–83. https://doi.org/10.18632/oncotarget.13957.CrossRefPubMed

125.

Jin K, Li T, Sanchez-Duffhues G, Zhou F, Zhang L. Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget. 2017;8(13):22145–65. https://doi.org/10.18632/oncotarget.13530.CrossRefPubMed

126.

Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526–36. https://doi.org/10.1038/onc.2009.211.CrossRefPubMedPubMedCentral

127.

Ha SY, Yu JI, Choi C, Kang SY, Joh JW, et al. Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma. Sci Rep. 2019;9(1):14738. https://doi.org/10.1038/s41598-019-50594-2.CrossRefPubMedPubMedCentral

128.

Yu X, Zheng H, Chan MT, Wu WK. HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med. 2017;21(2):410–7. https://doi.org/10.1111/jcmm.12956.CrossRefPubMed

129.

Li SP, Xu HX, Yu Y, He JD, Wang Z, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016;7(27):42431–46. https://doi.org/10.18632/oncotarget.9883.CrossRefPubMedPubMedCentral

130.

Sphyris N, Mani SA. pIgR: frenemy of inflammation, EMT, and HCC progression. J Natl Cancer Inst. 2011;103(22):1644–5. https://doi.org/10.1093/jnci/djr421.CrossRefPubMedPubMedCentral

131.

Ai J, Tang Q, Wu Y, Xu Y, Feng T, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst. 2011;103(22):1696–712. https://doi.org/10.1093/jnci/djr360.CrossRefPubMedPubMedCentral

132.

Critelli R, Milosa F, Faillaci F, Condello R, Turola E, et al. Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. Cell Death Dis. 2017;8(8): e3017. https://doi.org/10.1038/cddis.2017.395.CrossRefPubMedPubMedCentral

133.

Zhang Y, Zhang J, Chen X, Yang Z. Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma. Int J Med Sci. 2021;18(2):364–71. https://doi.org/10.7150/ijms.49790.CrossRefPubMedPubMedCentral

134.

Ben Mousa A. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008;14(1):40–2. https://doi.org/10.4103/1319-3767.37808.CrossRefPubMed

135.

Lv X, Fang C, Yin R, Qiao B, Shang R, et al. Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget. 2017;8(62):105340–55. https://doi.org/10.18632/oncotarget.22186.CrossRefPubMedPubMedCentral

136.

Zhang QJ, Wan L, Xu HF. High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Math Biosci Eng. 2019;16(6):7375–83. https://doi.org/10.3934/mbe.2019368.CrossRefPubMed

137.

Lozano-Ruiz B, Gonzalez-Navajas JM. The emerging relevance of AIM2 in liver disease. Int J Mol Sci. 2020;21(18). https://doi.org/10.3390/ijms21186535.

138.

Chen SL, Liu LL, Lu SX, Luo RZ, Wang CH, et al. HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis. Mol Oncol. 2017;11(9):1225–40. https://doi.org/10.1002/1878-0261.12090.CrossRefPubMedPubMedCentral

Titel: EMT and Inflammation: Crossroads in HCC
verfasst von: Burcu Sengez
Brian I. Carr
Hani Alotaibi
Publikationsdatum: 12.01.2022
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2023
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-021-00801-z

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

EMT and Inflammation: Crossroads in HCC

Abstract

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Colorectal Cancer Prevalence and Survival in Cuenca (Spain)

Endoluminal Leiomyoma of the Gastric Antrum: a Report of a Rare Case

Undetectable Brain Metastasis of Hepatocellular Carcinoma by PET-CT After Liver Transplantation: a Case Report

Quality Indicators and Outcomes in a Prospective Cohort of Colorectal Cancer Patients

Design and Characterization of Silver Nanoparticles of Different Species of Curcuma in the Treatment of Cancer Using Human Colon Cancer Cell Line (HT-29)

Impact of the COVID-19 Pandemic on Colorectal Cancer Diagnosis and Treatment: a Systematic Review

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie